Abstract: A composition composed of xylooligosaccharide, arabinogalactan, inulin, Ganoderma lucidum beta glucan, insoluble yeast ? (1, 3/1, 6)-glucan, soluble oat ? (1,3/1, 4)-glucan, and insoluble dried Saccharomyces cerevisiae fermentate, with a Bacillus coagulans component, for use in improving or maintaining digestive health, weight and glucose balance and boosting immunity is provided.
Abstract: The present invention provides a Bifidobacterium lactis GKK2, a composition comprising thereof and its use for improving asthma, especially for lowering airway resistance, reducing levels of non-specific and specific IgE in serum, alleviating bronchoconstriction and increasing levels of GSH reductase in liver tissue interstitial fluid to improve allergic asthma.
Abstract: The present invention provides a Bifidobacterium lactis having active substances, a composition comprising the same, and a method of promoting longevity using the same by subjecting the composition to a subject, thereby increasing Cisd2 gene expression, reducing damage of mitochondria, delaying aging-related symptoms including nerve degeneration and sarcopenia, and so on.
Abstract: Probiotic material to allow exposure of a baby born by non-natural childbirth, to bacterial flora that simulates that obtained during the natural birth process. A topical probiotic is described that is put on a baby when it is first born, and mimics the bacteria in the mother's vaginal canal. This topical probiotic re-creates the bacteria that the baby would have received had the baby been naturally born. In embodiments, a bacterial culture of the probiotic material includes at least Lactobacillus crispatus, Lactobacillus iners, Lactobacillus. jensenii, and Lactobacillus gasseri.
Abstract: The present invention relates to a topical composition of facilitating wound healing and reducing scars, which includes an inactivated culture of Lactobacillus species as an effective ingredient and can significantly facilitate wound healing as well as reducing scars, thereby can be applied to a method of facilitating wound healing and reducing scars.
Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.
Abstract: The present invention provides an active substance of Lactic Acid Bacteria, a composition comprising thereof and its use for promoting longevity, especially for increasing Cisd2 gene expression, reducing mitochondrial damage and delaying aging conditions such as nerve degeneration and sarcopenia.
Abstract: Embodiments of the disclosure encompass methods of treating or preventing an autoimmune disease in an individual. In particular cases, methods comprise administering for delivery to an individual a composition of microbiota. In certain cases, the composition comprises a population of one or more microbiota capable of producing one or more short-chain fatty acids.
Type:
Application
Filed:
April 11, 2018
Publication date:
February 20, 2020
Inventors:
Cintia S. De Paiva, Stephen C. Pflugfelder, Robert Allen Britton
Abstract: The respiratory microbiomes of neonates and those with bronchopulmonary disease have been characterized. Provided are probiotic compositions, which can include at least one living bacterial strain and at least one killed bacterial strain, that can comprise a combination of Lactobacilli species, 5 that when delivered to the bronchi or lungs of a patient can provide a reduction in the symptoms of a bronchopulmonary disease.
Type:
Application
Filed:
April 4, 2018
Publication date:
February 20, 2020
Inventors:
Charitharth Vivek Lal, Namasivayam Ambalavanan, Amit Gaggar, Casey Morrow
Abstract: A pharmaceutical composition comprising: a) an effective amount of one or more lytic bacteriophages specific against Fusobacterium nucleatum selected from Fnp?02-14, Fnp?11 and Fnn?107 or mixtures of them; and b) one or more pharmaceutically acceptable carrier and/or excipients. Method for preventing and/or treating diseases associated with Fusobacterium nucleatum and the use of the pharmaceutical composition for treating a disease associated with Fusobacterium nucleatum of the oral cavity such as V periodontal disease, among others.
Abstract: The present invention relates to Siphoviridae bacteriophage Ent-FAP-4 (accession number KCTC 12854BP), separated from nature, which is capable of specifically killing Enterococcus faecium and has a genome expressed by sequence number 1, a pharmaceutical composition, which comprises same as an active ingredient, and a method for preventing or treating diseases, induced by Enterococcus faecium, by means of the pharmaceutical composition.
Type:
Application
Filed:
January 11, 2018
Publication date:
February 20, 2020
Inventors:
Seong Jun Yoon, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Sang Hyeon Kang
Abstract: The present invention provides cannabis oil extracts and compositions thereof, including cannabis oil compositions containing vitamin E, and methods for preparing the extracts and compositions. In some embodiments, the present invention provides a method for preparing a cannabis oil extract comprising eluting cannabinoids from cannabis plant material with a solvent to produce an eluate, filtering the eluate with a filter to produce a filtrate, evaporating the solvent from the filtrate with a distiller to produce a distillate, and purging the distillate under conditions sufficient to remove residual solvent, thereby preparing the extract. In some embodiments, the method further includes mixing a quantity of vitamin E with the extract to produce a cannabis oil composition.
Type:
Application
Filed:
August 20, 2019
Publication date:
February 20, 2020
Applicant:
Constance Therapeutics, Inc.
Inventors:
Constance Finley, Luke McKee, Haley Poole Bestwick, Paul Roethle
Abstract: Provided are compositions and methods of forming a particulate material derived from a cannabis plant. The method includes introducing a component including at least one of: (i) a cannabinoid, and (ii) a terpene, to a polymer to produce a polymeric mixture. The component is dispersed in the polymeric mixture, which is then at least partially dehydrated to encapsulate the component within a polymeric material derived from the polymer. The polymeric material is water soluble. The dehydrated polymeric mixture is processed to form particulates comprising the component encapsulated within shells formed from the polymeric material.
Abstract: The present invention is directed to films made with edible polymers and containing a portion of finely ground olive leaf powder (OLP) suitable for preparing a hot or cold beverage and delivering an unexpectedly powerful quantity of natural anti-oxidant in the form of polyphenols.
Type:
Application
Filed:
July 24, 2017
Publication date:
February 20, 2020
Inventors:
Josephine Musco, James Rossman, Richard Fielder
Abstract: The present invention relates to novel black cumin extract compositions and a green process for making the composition. The black cumin extract composition of the invention can be used to treat anxiety, sleep and stress disorders along with significant effect on memory enhancement. The composition is available in oil and powder forms.
Abstract: Provided is a composition comprising a plant extract. The plant extract includes a citrus extract and a green tea extract. The extract combination can effectively increase expression of GLUT4 gene.
Abstract: The present invention relates to compositions comprising a water soluble tomato extract (WSTE) which may be used in maintaining cardiovascular health, lessening the risk of developing cardiovascular health problems, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject exposed, or is at risk of exposure, to particulate air pollution.
Type:
Application
Filed:
November 2, 2017
Publication date:
February 20, 2020
Applicant:
Provexis Natural Products Limited
Inventors:
Bernd MUSSLER, Daniel RAEDERSTORFF, Nathalie RICHARD
Abstract: An oral dosage form or plurality of oral dosage forms comprising as active ingredients combinations of citric acid, magnesium citrate, phytin, pyridoxine, and musa is disclosed. The oral dosage form(s) is useful for inhibiting calcium oxalate crystal growth and for treating or inhibiting growth of kidney stones. Methods of inhibiting calcium oxalate crystal growth and of treating or preventing kidney stones are also disclosed.
Type:
Application
Filed:
October 25, 2019
Publication date:
February 20, 2020
Inventors:
Gregory K. Hayer, Brendan Magrab, Henry R. Wolfe
Abstract: The present invention relates to a composition and a method of utilizing Gastrodia elata extract or an adenosine analog to promote neurogenesis, wherein the G. elata extract includes gastrodin, gastrodigenin, parishins, N6-(4-hydroxybenzyl) adenosine (T1-11) and 4-hydroxybenzaldehyde. The G. elata extract of the present invention exhibits anti-aging activity on nerve cells and can induce neurogenesis in mouse hippocampus.
Abstract: Two peptides that can selectively bind to SEVI and block the enhanced infectivity that results from the interaction of SEVI with HIV. The two peptides comprise the amino acid sequences FEEIVQEIEDFLENLV (SEQ. ID NO: 1) and GIGAVLEVLTTGLPALISWIEEEEQQ (SEQ. ID. NO: 2). The peptides may be administered topically, either alone or in combination with other prophylactics, agents, etc.
Abstract: Methods of treating the effects of disruption of normal blood flow in the CNS in an individual subject in need thereof are provided according to aspects of the present invention which include administering a therapeutically effective dose of exogenous NeuroD1 to an area where normal blood flow has been disrupted. Compositions are provided including 1) a recombinant adeno-associated adenovirus expression vector comprising a glial cell specific promoter operably linked to a nucleic acid encoding a site-specific recombinase and 2) a recombinant adeno-associated adenovirus expression vector comprising a ubiquitous promoter operably linked to a nucleic acid encoding NeuroD1, wherein the nucleic acid encoding NeuroD1 is inverted and flanked by two sets of site-specific recombinase recognition sites such that action of the recombinase irreversibly inverts the nucleic acid encoding NeuroD1 such that NeuroD1 is expressed in a mammalian cell.
Abstract: The composition of the present invention can inhibit homologous human T cell reaction and the phenomenon of infiltration which reduces skin graft damage in vivo, thereby enabling prompt, rapid and effective graft rejection prevention or treatment effects at a low concentration. In addition, the present invention has advantages of successfully controlling in vivo human T cell reactions, as compared with conventional therapeutic agents, thus providing few side effects, the possibilities of local high-dose administration of therapeutic agents and potentially new treatments and prescriptions.
Abstract: Provided herein are variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of FGF19 and/or FGF21, and variants or fusions of FGF19 and/or FGF21 proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Abstract: Methods of stimulating collagen production, including stimulation of chondrocyte production, at the site of a defect. Methods include administering to the site of a defect at least two proteins from the group IL-1ra, sTNF-RI, sTNF-RII, IGF-I, EGF, HGF, PDGF-AB, PDGF-BB, VEGF, TGF-?1, and sIL-1RII.
Type:
Application
Filed:
October 28, 2019
Publication date:
February 20, 2020
Inventors:
Andrea Matuska, Krista Toler, Jennifer E. Woodell-May
Abstract: Methods and pharmaceutical compositions of a unique Biologic Response Modifier (BRM) that does not suppress the immune system, yet provides protection of beta cells in those with type 1 diabetes and those at risk for type 1 diabetes are described. The methods include utilization of BRMs in combination with islet neogenesis therapies, beta regeneration therapies, islet, beta cell or stem cell transplants, or devices housing islets, beta cells or stem cells for treatment and prevention of type 1 patients and related conditions. The compositions and methods provide for beta cell protection from autoimmune attack for prevention or delay in the onset of type 1 diabetes. The BRM may be used in conjunction with immunosuppressive agents. The BRM may also be used in other conditions found among patients with type 1 diabetes and their relatives for whom there is no treatment or current therapy is unsuccessful.
Abstract: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
Type:
Application
Filed:
June 14, 2019
Publication date:
February 20, 2020
Inventors:
Thomas R. Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
Abstract: Application for MDR TNBC significantly increasing the efficacy of TNBC treatment and address a global health concern by blocking the ability of mitochondria to fuse together and with other organelles through a nanomedicine therapy. The development of a dual targeted nanomedicine therapy targeting the epidermal growth factor receptor on the surface of TNBC cancers cells and subcellular targeting of mitochondria through mitofusin 2 (MFN2) targeting (mitofusin mediates inter-mitochondrial fusion and fusion of mitochondria with the endoplasmic reticulum). The combination therapy delivers an MFN2-peptidepolymer construct for blocking MFN2 along with a low dose of BAM? (a BAX activator).
Abstract: According to the invention, a novel combination composition and method of treatment for thrombotic disorders, e.g., STEMI in ACS patients, is disclosed. The present invention relates to thrombin analogs, e.g., WE and E-WE thrombin analogs, in combination with fibrinolytics, e.g., tPA. In particular, E-WE thrombin analog and fibrinolytic combination therapy for inhibition of thrombin mediated TAFi activation and acceleration of tPA induced thrombolysis with E-WE thrombin. The present invention also relates to methods of treating a subject having a thrombotic or thromboembolic disorder by delivering the novel composition comprised of at least one antithrombotic thrombin analog and at least one fibrinolytic agent to the subject.
Type:
Application
Filed:
November 2, 2017
Publication date:
February 20, 2020
Inventors:
Erik Ian Tucker, Brandon Davis Markway, Michael Nikolaus Wallisch, Nora Green Verbout
Abstract: The present invention provides methods for large scale preparation of sterile stable liquid thrombin composition comprised of glycerol; stable liquid thrombin compositions; and hemostatic composition and kits. The present invention further provides hemostatic compositions comprised of liquid thrombin, glycerol and gelatin. Further provided herein is a method for the large-scale production of a sterile liquid thrombin composition comprised of glycerol.
Abstract: This disclosure provides materials and methods for treating or preventing graft-versus-host-disease (GVHD) using protein C or activated protein C or a signaling-selective variant or mutant thereof.
Type:
Application
Filed:
October 20, 2017
Publication date:
February 20, 2020
Inventors:
Bruce R. Blazar, John H. Griffin, Ryan P. Flynn, Ranjeet K. Sinha
Abstract: The present invention provides methods for improving observed or determined efficacy by administration of agents to more severely diseased subjects, as contrasted with less severely diseased subjects. The present disclosure specifically demonstrates that, with respect to treatment of certain skin conditions, and particularly conditions associated with dysregulated and/or diseased skin cells, administration to more severely diseased subjects improves observed or determined efficacy.
Abstract: The invention provides humanized anti-Siglec-8 antibodies and their use in treating and preventing eosinophil-mediated disorders and/or mast cell-mediated disorders, as well as compositions and kits comprising the humanized anti-Siglec-8 antibodies.
Type:
Application
Filed:
May 17, 2019
Publication date:
February 20, 2020
Applicant:
Allakos Inc.
Inventors:
Christopher R. BEBBINGTON, Rustom FALAHATI, Carolina Rita SOUSA FERNANDES, David John MATTHEWS, Nenad TOMASEVIC, Jason WILLIAMS, John LEUNG
Abstract: The gist of the invention consists in the therapeutic vaccine for treatment of diabetes type 1 in children, which contains Treg cells CD3(+)CD4(+)CD25(high)CD127(?). Claimed too is the cell sorter used to produce the vaccine and the method of multiplying Treg cells in vitro.
Type:
Application
Filed:
October 23, 2019
Publication date:
February 20, 2020
Inventors:
Piotr Trzonkowski, Malgorzata Mysliwiec, Natalia Marek-Trzonkowska
Abstract: The compositions described herein include an epitope of a peptide that may elicit an immune response in a subject following administration. The compositions may comprise nucleic acids. The compositions may comprise peptides. The methods described herein include administering a composition comprising an epitope of a peptide to a subject in need thereof.
Type:
Application
Filed:
March 29, 2019
Publication date:
February 20, 2020
Inventors:
Mary L. Disis, Denise Cecil, Meredith Slota
Abstract: A cancer therapy composition and a method of cancer treatment by inducing humoral and cellular immune responses against cancer cells in a patient is provided. The method includes administering to the patient a therapeutically effective amount of a vaccine, wherein the vaccine includes at least one tumor-associated antigen, at least one immunostimulant, and at least one lipid capable of forming a multilamellar liposome, or non-lipid molecule capable of forming a vesicle or gel. A therapeutically effective amount of at least one cell-based immunotherapeutic agent is also administered to the patient before, after, or at the same time the vaccine is administered to the patient.
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
October 31, 2019
Publication date:
February 20, 2020
Inventors:
Andrea MAHR, Toni WEINSCHENK, Anita WIEBE, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
Abstract: Methods described herein relate to constructing therapeutic fusion-specific vaccine libraries, selecting a therapeutic fusion-specific vaccine for a cancer patient, and/or constructing a de novo therapeutic fusion-specific vaccine for patients having a gene fusion that is absent from a fusion-specific vaccine library.
Type:
Application
Filed:
November 1, 2019
Publication date:
February 20, 2020
Applicant:
BostonGene Corporation
Inventors:
Maksym Artomov, Feliks Frenkel, Igor Golubev, Olga Zolotareva
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Application
Filed:
November 4, 2019
Publication date:
February 20, 2020
Inventors:
Andrea MAHR, Toni WEINSCHENK, Oliver SCHOOR, Jens FRITSCHE, Harpreet SINGH
Abstract: Systems and methods are presented that allow for selection of tumor neoepitopes that are then used to generate recombinant nucleic acids that encode one or more polytopes that are optimized for proper trafficking and processing. In preferred methods, the polytopes are encoded in a plasmid and/or a viral expression system for use as a therapeutic agent.
Abstract: The present disclosure provides immunomodulatory compositions comprising heat-killed Caulobacter crescentus (HKCC). Immunomodulatory compositions of the present disclosure are useful for modulating an immune response in an individual. The present disclosure thus provides methods of modulating an immune response in an individual, involving administering an immunomodulatory composition comprising HKCC to the individual.
Abstract: The disclosure relates to a glycoconjugate vaccine conferring protection against Francisella tularensis infections and a method to manufacture a glycoconjugate antigen.
Type:
Application
Filed:
September 11, 2017
Publication date:
February 20, 2020
Applicant:
London School of Hygiene and Tropical Medicine
Inventors:
Brendan Wren, Jon Cuccui, Madeleine Moule
Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.
Type:
Application
Filed:
February 20, 2018
Publication date:
February 20, 2020
Applicant:
Merck Sharp & Dohme Corp.
Inventors:
Jian He, John E. MacNair, William J. Smith, Michael A. Winters, Joseph G. Joyce, Chitrananda Abeygunawardana, Luwy Musey, Hari Pujar, Julie M. Skinner, Emily Wen, Patrick McHugh, John Michael Williams, Catherine Lancaster
Abstract: Isolated peptides comprising one or more antigenic sites of filovirus glycoprotein and methods of their use and production are disclosed. Nucleic acid molecules encoding the peptides are also provided. In several embodiments, the peptides can be used to induce an immune response to filovirus glycoprotein, such as Zaire ebolavirus glycoprotein, in a subject, for example, to treat or prevent infection of the subject with the virus.
Type:
Application
Filed:
October 31, 2017
Publication date:
February 20, 2020
Applicant:
The United States of America, as represented by the Secretary, Department Health and Human Service
Abstract: A vaccine composition and method of vaccination are provided useful for immunizing a subject against a rotavirus. The vaccines include rotavirus strains CDC-9 and CDC-66, fragments thereof, homologues thereof, or combinations thereof. Inventive vaccines may include a fragment of CDC-9, CDC-66, homologues thereof, or combinations thereof. Methods of inducing an immunological response are provided by administering an inventive vaccine.
Type:
Application
Filed:
November 1, 2019
Publication date:
February 20, 2020
Applicant:
The U.S.A., as represented by the Secretary, Department of Health and Human Services
Inventors:
Baoming Jiang, Roger I. Glass, Yuhuan Wang, Jon Gentsch
Abstract: Provided herein are, inter alia, methods and compositions including T cells expressing (i) a recombinant CAR protein which includes a peptide binding site and is capable of specifically binding cancer-specific antigens and (ii) a T cell receptor specific for a viral antigen (e.g., a CMV pp65 protein). The engineered T cells provided herein may be used in combination with a viral vaccine (e.g. cytomegalovirus (CMV) Triplex Vaccine) to treat a variety of cancers. The methods described herein also permit in viva expansion of CMV-specific CAR T cells, instead of or in addition to ex vivo expansion, avoiding excessive T cell exhaustion that results in some cases from ex vivo manufacturing.
Type:
Application
Filed:
October 19, 2017
Publication date:
February 20, 2020
Inventors:
John C. WILLIAMS, Christine BROWN, Don J. DIAMOND
Abstract: The disclosure relates to herpes simplex virus (HSV) ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Type:
Application
Filed:
April 25, 2018
Publication date:
February 20, 2020
Applicant:
Modema TX, Inc.
Inventors:
Giuseppe Ciaramella, Shinu John, Andrew J. Bett, Danilo R. Casimiro, Dai Wang, Lan Zhang
Abstract: The present disclosure relates to improved oral immunotherapy methods for treating peanut allergy. The disclosure provides methods for treating a subject for a peanut allergy by an oral immunotherapy comprising an up-dosing phase and a maintenance phase. In certain embodiments, the methods comprise non-daily administration to the subject of a maintenance phase dose. In certain embodiments, the methods comprise administering a maintenance phase dose for more than 24 weeks. In other embodiments, the disclosure provides methods for reducing the risk of an allergic adverse event in a subject receiving an oral immunotherapy dosage therapy.
Abstract: Methods for the production of immunogenic compositions containing a non-natural amino acid are disclosed. The non-natural amino acid can be a site for attachment of antigens, such as bacterial capsular polysaccharides, to make immunogenic conjugates. Bio-orthogonal attachment chemistry incorporated into the non-natural amino acids allows for more efficient and potent antigen presentation to the immune system, simplified purification, and more well-defined structure of these semi-synthetic immunogens.
Type:
Application
Filed:
July 1, 2019
Publication date:
February 20, 2020
Inventors:
Jeffery C. FAIRMAN, Jon H. HEINRICHS, Wei CHAN, Olivier Jean Gérard MARCQ, Christopher R. Behrens